

(Sharecast News) - Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseas...


(Sharecast News) - Syncona announced on Thursday that it has committed £63.5m in series B financing to Resolution Therapeutics, a portfolio compa...


(Alliance News) - Syncona Ltd on Thursday said it has committed GBP63.5 million in a series B financing of Resolution Therapeutics, which will be put ...

(Alliance News) - Syncona Ltd on Friday said that its portfolio company, Beacon Therapeutics Holdings Ltd, has presented data at a conference in Barce...


(Alliance News) - Syncona Ltd on Thursday announced that Achilles Therapeutics will discontinue its lead TIL-based cNeT program, close its Phase I/IIa...


(Sharecast News) - Life science investor Syncona reported significant developments in its portfolio during its first quarter on Tuesday, despite a sli...


(Alliance News) - Syncona Ltd on Tuesday reported a decline in first quarter net asset value, reflecting mixed investment fortunes.